Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. · 2010
Read Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). by Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2853094.txt.
Description
Northover and colleagues reported in 2010 the thirteen-year follow-up of ACT I, the first British randomized trial of chemoradiation for anal cancer. The trial's 1996 results had already made combined chemotherapy and radiation the standard over radiation alone. This update tracked all five hundred seventy-seven randomized patients for relapses and deaths through 2007.
The benefit endured and grew clearer with time. For every hundred patients given chemoradiation, about twenty-five fewer suffered local relapse and about twelve fewer died of anal cancer by twelve years. An early bump in deaths from other causes faded away by year ten. Only eleven patients relapsed locally after year five, a fact the authors say should shape how future trials choose their endpoints.
Catalog record
| CREATOR | Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |